» Articles » PMID: 20179752

DNA Methylation Profiles of Ovarian Epithelial Carcinoma Tumors and Cell Lines

Overview
Journal PLoS One
Date 2010 Feb 25
PMID 20179752
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Epithelial ovarian carcinoma is a significant cause of cancer mortality in women worldwide and in the United States. Epithelial ovarian cancer comprises several histological subtypes, each with distinct clinical and molecular characteristics. The natural history of this heterogeneous disease, including the cell types of origin, is poorly understood. This study applied recently developed methods for high-throughput DNA methylation profiling to characterize ovarian cancer cell lines and tumors, including representatives of three major histologies.

Methodology/principal Findings: We obtained DNA methylation profiles of 1,505 CpG sites (808 genes) in 27 primary epithelial ovarian tumors and 15 ovarian cancer cell lines. We found that the DNA methylation profiles of ovarian cancer cell lines were markedly different from those of primary ovarian tumors. Aggregate DNA methylation levels of the assayed CpG sites tended to be higher in ovarian cancer cell lines relative to ovarian tumors. Within the primary tumors, those of the same histological type were more alike in their methylation profiles than those of different subtypes. Supervised analyses identified 90 CpG sites (68 genes) that exhibited 'subtype-specific' DNA methylation patterns (FDR<1%) among the tumors. In ovarian cancer cell lines, we estimated that for at least 27% of analyzed autosomal CpG sites, increases in methylation were accompanied by decreases in transcription of the associated gene.

Significance: The significant difference in DNA methylation profiles between ovarian cancer cell lines and tumors underscores the need to be cautious in using cell lines as tumor models for molecular studies of ovarian cancer and other cancers. Similarly, the distinct methylation profiles of the different histological types of ovarian tumors reinforces the need to treat the different histologies of ovarian cancer as different diseases, both clinically and in biomarker studies. These data provide a useful resource for future studies, including those of potential tumor progenitor cells, which may help illuminate the etiology and natural history of these cancers.

Citing Articles

MicroRNAs Associated with IgLON Cell Adhesion Molecule Expression.

Salluzzo M, Vianello C, Flotta F, Rimondini R, Carboni L Curr Issues Mol Biol. 2024; 46(7):7702-7718.

PMID: 39057097 PMC: 11276434. DOI: 10.3390/cimb46070456.


Current Applications and Challenges of Next-Generation Sequencing in Plasma Circulating Tumour DNA of Ovarian Cancer.

Roque R, Ribeiro I, Figueiredo-Dias M, Gourley C, Carreira I Biology (Basel). 2024; 13(2).

PMID: 38392306 PMC: 10886635. DOI: 10.3390/biology13020088.


The role of DNA methylation in ovarian cancer chemoresistance: A narrative review.

Song K, Artibani M Health Sci Rep. 2023; 6(5):e1235.

PMID: 37123549 PMC: 10140645. DOI: 10.1002/hsr2.1235.


Role of DNA methylation in the relationship between glioma risk factors and glioma incidence: a two-step Mendelian randomization study.

Howell A, Relton C, Martin R, Zheng J, Kurian K Sci Rep. 2023; 13(1):6590.

PMID: 37085538 PMC: 10121678. DOI: 10.1038/s41598-023-33621-1.


Review the progression of ovarian clear cell carcinoma from the perspective of genomics and epigenomics.

Tong A, Di X, Zhao X, Liang X Front Genet. 2023; 14:952379.

PMID: 36873929 PMC: 9978161. DOI: 10.3389/fgene.2023.952379.


References
1.
Lowe K, Shah C, Wallace E, Anderson G, Paley P, McIntosh M . Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17(9):2480-7. PMC: 2632599. DOI: 10.1158/1055-9965.EPI-08-0150. View

2.
Barr H, Hermann A, Berger J, Tsai H, Adie K, Prokhortchouk A . Mbd2 contributes to DNA methylation-directed repression of the Xist gene. Mol Cell Biol. 2007; 27(10):3750-7. PMC: 1900000. DOI: 10.1128/MCB.02204-06. View

3.
Takai D, Jones P . Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A. 2002; 99(6):3740-5. PMC: 122594. DOI: 10.1073/pnas.052410099. View

4.
Lutz A, Willmann J, Cochran F, Ray P, Gambhir S . Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes. PLoS Med. 2008; 5(8):e170. PMC: 2517618. DOI: 10.1371/journal.pmed.0050170. View

5.
Brunner A, Johnson D, Kim S, Valouev A, Reddy T, Neff N . Distinct DNA methylation patterns characterize differentiated human embryonic stem cells and developing human fetal liver. Genome Res. 2009; 19(6):1044-56. PMC: 2694474. DOI: 10.1101/gr.088773.108. View